Inaedis is a biopharmaceutical technology company developing a scalable, cGMP-compatible platform that removes the fundamental formulation, manufacturing, and delivery constraints limiting today’s biologics. Originating from research at Princeton University, Inaedis was founded to address a critical industry problem: most biologics remain expensive, fragile, cold-chain dependent, and tied to invasive administration routes.
Biologics now account for nearly half of prescription drug spending, yet their impact is constrained by instability, complex logistics, and IV-centric delivery. Conventional formulation and drying technologies—lyophilization and spray drying—are energy intensive, poorly scalable, and impose thermal and mechanical stresses that damage sensitive biologics. These limitations drive high costs, manufacturing risk, cold-chain failures, and limited patient access.
Inaedis was created to change this equation.